GETI-B Getinge AB (publ)
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardiothoracic surgery equipment, peripheral stenting, OEM solutions, and beating heart surgery equipment; and operating room equipment, anesthesia, advanced patient monitoring, and operating room integration solutions. Further, it offers pre-cleaning, cleaning and disinfection, sterilization, consumables, endoscope reprocessing, and sterile supply management solutions; connected medical devices, and patient flow management; and low temperature sterilization, biocontainment in vaccine production, terminal sterilization, sterile isolation technology, cleaning and sterilization, aseptic transfer, and large-scale cultivation. Additionally, the company provides bioreactor preparation solution, bioprocess development and optimization, labware cleaning and sterilization, biocontainment, and vivarium. It offers its products through a network of sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia and Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Getinge (STO: GETI-B)
›
Getinge (STO: GETI-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 11,847 employees.
The shares were at 280.00 SEK on 19 November 2026, up 38.3% over 52 weeks. Its 52-week range is 175.90 SEK to 283.80 SEK: the price is 1.3% below the high and 59.2% above the low.
At a market capitalisation of 76.26B SEK, it trades at 26.9 times trailing earnings and 25.6 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, so GETI-B is valued in line with them. It pays a dividend yielding 1.71% (it pays out 46% of its earnings), against a median of 2.36% among the dividend payers in that peer group.
Getinge reports return on equity of 7.7%, an operating margin of 14.3% and revenue up 2.7% year over year.
Its debt exceeds its cash by 8.08B SEK, a debt-to-equity ratio of 0.37. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 11 analysts cover the stock; their mean price target of 272.91 SEK is 2.5% below the current price. The next earnings report is expected on 26 January 2027.